Korro Bio — Third Quarter 2026 Earnings Summary

Korro Bio initiated dosing of healthy volunteers in the Phase 1/2 ANCHOR clinical trial for its RNA-editing candidate KRRO-121, with plans to begin treating patients with urea cycle disorders in the first half of 2027. The company reported best-in-class preclinical data for KRRO-111, demonstrating over 95% editing of SERPINA1 transcripts in mouse models, and intends to submit a regulatory application in the first half of 2027. For the third quarter ended September 30, 2026, Korro reported a net loss of $17.5 million and ended the period with $124.8 million in cash, cash equivalents, and marketable securities, supporting operations into the second half of 2028.